Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 13/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 11/20 | 1.00 |
| ▸ | LMNA | P02545 | 9/20 | 1.00 |
| ▸ | TSHR | P16473 | 5/20 | 1.00 |
| ▸ | TP53 | P04637 | 4/20 | 1.00 |
| ▸ | NR2F2 | P24468 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | POLB | P06746 | 1/20 | 1.00 |
| ▸ | NPC1 | O15118 | 13/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.61 |
| ▸ | HTT | P42858 | 4/20 | 0.61 |
| ▸ | MAPT | P10636 | 8/20 | 0.60 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | ESR1 | P03372 | 2/20 | 0.54 |
| ▸ | USP2 | O75604 | 1/20 | 0.54 |
| ▸ | RECQL | P46063 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4114205 | 0.76 | RAB9A (0.81) | RAB9ASMN1; SMN2LMNATSHRTP53 | |
| SCHEMBL17456958 | 0.74 | SMN1; SMN2 (1.00) | RAB9ASMN1; SMN2LMNATSHRTP53 | |
| SCHEMBL15987441 | 0.73 | RAB9A (0.66) | RAB9ASMN1; SMN2LMNATSHRTP53 | |
| SCHEMBL20741111 | 0.73 | SMN1; SMN2 (0.61) | RAB9ASMN1; SMN2LMNATSHRTP53 | |
| SCHEMBL30865112 | 0.69 | MAPT (1.00) | RAB9ASMN1; SMN2LMNATSHRTP53 | |
| SCHEMBL24834367 | 0.68 | RAB9A (0.59) | RAB9ASMN1; SMN2LMNATSHRTP53 | |
| SCHEMBL21003276 | 0.67 | RAB9A (0.51) | RAB9ASMN1; SMN2LMNATSHRTP53 | |
| SCHEMBL12529979 | 0.66 | RAB9A (0.62) | RAB9ASMN1; SMN2LMNATSHRTP53 | |
| SCHEMBL266418 | 0.65 | RAB9A (0.54) | RAB9ASMN1; SMN2LMNATSHRTP53 | |
| SCHEMBL21332824 | 0.64 | S1PR2 (0.67) | RAB9ASMN1; SMN2LMNATSHRTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220249436-A1 | Small Molecule Agonists and Antagonists of NR2F6 Activity in Humans | KCL THERAPEUTICS, INC (US) | 2022-08-11 | — | — | US | disclosed |
| US-11377442-B2 | Small molecule agonists and antagonists of NR2F6 activity | Zander Biologics, Inc (US) | 2022-07-05 | — | — | US | disclosed |
| US-11324719-B2 | Small molecule agonists and antagonists of NR2F6 activity in humans | KCL THERAPEUTICS, INC. (US) | 2022-05-10 | — | — | US | disclosed |
| US-11241427-B2 | Small molecule modulators of NR2F6 activity | KCL THERAPEUTICS, INC. (US) | 2022-02-08 | — | — | US | disclosed |
| US-20200071307-A1 | SMALL MOLECULE AGONISTS AND ANTAGONISTS OF NR2F6 ACTIVITY IN ANIMALS | Zander Therapeutics, Inc. (US) | 2020-03-05 | — | — | US | disclosed |
| US-10472351-B2 | Small molecule agonists and antagonists of NR2F6 activity in animals | Zander Therapeutics, Inc. (US) | 2019-11-12 | — | — | US | disclosed |
| US-20190054118-A1 | Small Molecule Agonists and Antagonists of NR2F6 Activity in Animals | Zander Therapeutics, Inc. | 2019-02-21 | — | — | US | disclosed |
| US-20180346456-A1 | SMALL MOLECULE AGONISTS AND ANTAGONISTS OF NR2F6 ACTIVITY | SYBLEU INC. | 2018-12-06 | — | — | US | disclosed |
| US-20180346455-A1 | SMALL MOLECULE AGONISTS AND ANTAGONISTS OF NR2F6 ACTIVITY IN ANIMALS | SYBLEU INC. | 2018-12-06 | — | — | US | disclosed |
| US-20180214413-A1 | Small Molecule Agonists and Antagonists of NR2F6 Activity in Humans | KCL THERAPEUTICS, INC | 2018-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180214413-A1 | Small Molecule Agonists and Antagonists of NR2F6 Activity in Humans | NR4A2, NR2C2, NR0B2 | RAB9A 3645/4885SMN1; SMN2 2344/4885LMNA 4829/4885 |
| US-20180346455-A1 | SMALL MOLECULE AGONISTS AND ANTAGONISTS OF NR2F6 ACTIVITY IN ANIMALS | NR4A2, NR2C2, NR0B2 | RAB9A 3469/4885SMN1; SMN2 2285/4885LMNA 4829/4885 |
| US-20200071307-A1 | SMALL MOLECULE AGONISTS AND ANTAGONISTS OF NR2F6 ACTIVITY IN ANIMALS | NR4A2, NR2C2, NR0B2 | RAB9A 3469/4885SMN1; SMN2 2285/4885LMNA 4829/4885 |
| US-11241427-B2 | Small molecule modulators of NR2F6 activity | NR2F2, NR2E3, NR2C2 | RAB9A 4128/4885SMN1; SMN2 2494/4885LMNA 4730/4885 |
| US-20220249436-A1 | Small Molecule Agonists and Antagonists of NR2F6 Activity in Humans | NR4A2, NR2C2, NR0B2 | RAB9A 3645/4885SMN1; SMN2 2344/4885LMNA 4829/4885 |
| US-20190054118-A1 | Small Molecule Agonists and Antagonists of NR2F6 Activity in Animals | NR4A2, NR2C2, NR0B2 | RAB9A 3469/4885SMN1; SMN2 2285/4885LMNA 4829/4885 |
| US-11324719-B2 | Small molecule agonists and antagonists of NR2F6 activity in humans | NR4A2, NR2C2, NR0B2 | RAB9A 3645/4885SMN1; SMN2 2344/4885LMNA 4829/4885 |
| US-11377442-B2 | Small molecule agonists and antagonists of NR2F6 activity | NR4A2, NR2C2, NR2F2 | RAB9A 3762/4885SMN1; SMN2 2982/4885LMNA 4840/4885 |
| US-10472351-B2 | Small molecule agonists and antagonists of NR2F6 activity in animals | NR4A2, NR2C2, NR0B2 | RAB9A 3469/4885SMN1; SMN2 2285/4885LMNA 4829/4885 |
| US-20180346456-A1 | SMALL MOLECULE AGONISTS AND ANTAGONISTS OF NR2F6 ACTIVITY | NR4A2, NR2C2, NR2F2 | RAB9A 3762/4885SMN1; SMN2 2982/4885LMNA 4840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.